|
Sponsors Resigned to Trials for Biosimilar Interchangeability, May Limit Pipelines
The FDA appears poised to require clinical trial data from drugmakers seeking biosimilar interchangeability designations, a move that could shrink the number of products that aim to achieve the standard, drugmakers and legal experts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives